Shenzhen Chipscreen Biosciences Co Ltd - Class A

NEW
SHSE:688321 (China)   Class A
Â¥ 26.18 +2.23 (+9.31%) Jun 29
110.00
P/B:
4.48
Market Cap:
Â¥ 11.60B ($ 1.71B)
Enterprise V:
Â¥ 11.63B ($ 1.72B)
Volume:
1.62B
Avg Vol (2M):
10.11M
Trade In:
Volume:
1.62B

Business Description

Description
Shenzhen Chipscreen Biosciences Co Ltd is engaged in the research and development of small molecule drugs.
Name Current Vs Industry Vs History
Cash-To-Debt
0.98
Equity-to-Asset
0.56
Debt-to-Equity
0.6
Debt-to-EBITDA
11.73
Interest Coverage
4.37
Piotroski F-Score
8/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
3.85
Distress
Grey
Safe
Beneish M-Score
-1.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
63.65
9-Day RSI
55.76
14-Day RSI
49.73
3-1 Month Momentum %
-9.5
6-1 Month Momentum %
-5.76
12-1 Month Momentum %
14.32

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
2.56
Quick Ratio
2.49
Cash Ratio
1.88
Days Inventory
153.98
Days Sales Outstanding
86.98
Days Payable
11.55

Dividend & Buy Back

Name Current Vs Industry Vs History
Dividend Yield %
0.22
Forward Dividend Yield %
0.22
5-Year Yield-on-Cost %
0.22
3-Year Average Share Buyback Ratio
0.2
Shareholder Yield %
-1.8
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Shenzhen Chipscreen Biosciences Co Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ¥) 1,004.837
EPS (TTM) (Â¥) 0.238
Beta 1.705
3-Year Sharpe Ratio 0.25
3-Year Sortino Ratio 0.46
Volatility % 67.58
14-Day RSI 49.73
14-Day ATR (Â¥) 1.111481
20-Day SMA (Â¥) 25.3775
12-1 Month Momentum % 14.32
52-Week Range (Â¥) 23.41 - 44.99
Shares Outstanding (Mil) 442.94

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Shenzhen Chipscreen Biosciences Co Ltd Filings

Filing Date Document Date Form
No Filing Data

Shenzhen Chipscreen Biosciences Co Ltd Stock Events

Financials Calendars
Event Date Price (Â¥)
CNY 0.058000 Cash Dividend 2026-05-14 31.03 (-0.54%)
Show
Entries

Shenzhen Chipscreen Biosciences Co Ltd Frequently Asked Questions

What is Shenzhen Chipscreen Biosciences Co Ltd(SHSE:688321)'s stock price today?
The current price of SHSE:688321 is ¥26.18. The 52 week high of SHSE:688321 is ¥44.99 and 52 week low is ¥23.41.
When is next earnings date of Shenzhen Chipscreen Biosciences Co Ltd(SHSE:688321)?
The next earnings date of Shenzhen Chipscreen Biosciences Co Ltd(SHSE:688321) is .
Does Shenzhen Chipscreen Biosciences Co Ltd(SHSE:688321) pay dividends? If so, how much?
The  Dividend Yield %  of Shenzhen Chipscreen Biosciences Co Ltd(SHSE:688321) is 0.22% (As of Today), Highest Dividend Payout Ratio of Shenzhen Chipscreen Biosciences Co Ltd(SHSE:688321) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Shenzhen Chipscreen Biosciences Co Ltd(SHSE:688321) is 0.22%. For more information regarding to dividend, please check our Dividend Page.

Press Release

Subject Date
Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Yearâ„¢ 2025 awards 2025-12-29
Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development 2025-07-31
The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved 2024-11-01
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted 2024-10-17
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting 2024-10-15
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma 2024-04-30
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis 2024-03-18
Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis 2023-11-02
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan 2021-12-01
Chipscreen Biosciences Announces NMPA New Drug Approval of Bilessglu® (Chiglitazar Sodium tablets) for ( Type 2 Diabetes) in China 2021-10-19
10/Page

Articles on Shenzhen Chipscreen Biosciences Co Ltd

No articles.